オマリズマブは、経口または注射のコルチコステロイドではコントロールできない重症で持続性のあるアレルギー性喘息の治療に使用される[5]。これらの患者は、すでにステップIからステップIVの治療に失敗し、ステップVの治療を受けている。このような治療法は、1993年に米国国立衛生研究所(National Institutes of Health)の米国国立心肺血液研究所(英語版)(National Heart, Lung, and Blood Institute)と世界保健機関(World Health Organization)が共同で立ち上げた医療ガイドラインである喘息管理に関する国際指針(英語版)(GINA、Global Initiative of Asthma)が発表した、喘息の管理と予防のために広く採用されているガイドラインと一致している[6]。
^Schulman ES (October 2001). “Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders”. Am J Respir Crit Care Med164 (8 Pt 2): S6–11. doi:10.1164/ajrccm.164.supplement_1.2103025. PMID11704611.
^Pocket guide for asthma management and prevention. Global Initiatives for Asthma. 2013. “Archived copy”. 2013年5月21日時点のオリジナルよりアーカイブ。2013年7月7日閲覧。
^ abUrgert, M.C.; Elzen, M.T.; Knulst, A.C.; Fedorowicz, Z.; Zuuren, E.J. (22 July 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and assessment”. British Journal of Dermatology173 (2): 404–415. doi:10.1111/bjd.13845. PMID25891046.
^ abBernstein, Jonathan A.; Kavati, Abhishek; Tharp, Michael D.; Ortiz, Benjamin; MacDonald, Karen; Denhaerynck, Kris; Abraham, Ivo (16 February 2018). “Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence”. Expert Opinion on Biological Therapy18 (4): 425–448. doi:10.1080/14712598.2018.1438406. PMID29431518.
^Zhao, Zuo-Tao; Ji, Chun-Mei; Yu, Wen-Jun; Meng, Ling; Hawro, Tomasz; Wei, Ji-Fu; Maurer, Marcus (June 2016). “Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials”. Journal of Allergy and Clinical Immunology137 (6): 1742–1750.e4. doi:10.1016/j.jaci.2015.12.1342. PMID27040372.
^“Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells”. Eur. J. Immunol.33 (4): 1030–40. (April 2003). doi:10.1002/eji.200323185. PMID12672069.
^“Omalizumab and the risk of malignancy: results from a pooled analysis”. The Journal of Allergy and Clinical Immunology129 (4): 983–9.e6. (April 2012). doi:10.1016/j.jaci.2012.01.033. PMID22365654.
^Chang TW (February 2000). “The pharmacological basis of anti-IgE therapy”. Nat. Biotechnol.18 (2): 157–62. doi:10.1038/72601. PMID10657120.
^ abc“Anti-IgE as a mast cell-stabilizing therapeutic agent”. The Journal of Allergy and Clinical Immunology117 (6): 1203–12. (June 2006). doi:10.1016/j.jaci.2006.04.005. PMID16750976.
^“Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody”. Journal of Immunology158 (3): 1438–45. (February 1997). PMID9013989.
^Scheinfeld N (2005). “Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody”. Dermatol. Online J.11 (1): 2. PMID15748543.
^“Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy”. Clin. Exp. Allergy35 (4): 408–16. (April 2005). doi:10.1111/j.1365-2222.2005.02191.x. PMID15836747.
^ ab“The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation”. The Journal of Allergy and Clinical Immunology115 (3): 459–65. (March 2005). doi:10.1016/j.jaci.2004.11.053. PMID15753888.
^“Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE”. Ann Allergy Asthma Immunol104 (6): 537–9. (June 2010). doi:10.1016/j.anai.2010.04.011. PMID20568389.
^“Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE”. Int. J. Urol.13 (5): 631–4. (May 2006). doi:10.1111/j.1442-2042.2006.01373.x. PMID16771742.
^“Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab”. The Journal of Allergy and Clinical Immunology120 (4): 979–81. (October 2007). doi:10.1016/j.jaci.2007.07.041. PMID17931567.
^de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry (April 2013). “Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry”. J Asthma50 (3): 296–301. doi:10.3109/02770903.2012.757780. PMID23350994.
^“Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria”. N Engl J Med368 (10): 924–35. (March 2013). doi:10.1056/NEJMoa1215372. PMID23432142.
^“Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy”. The Journal of Allergy and Clinical Immunology132 (1): 101–9. (July 2013). doi:10.1016/j.jaci.2013.05.013. PMID23810097.
Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. Journal of Allergy and Clinical Immunology. 2017 May 1;139(5):1489-95.
Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomised, double-blind, placebo-controlled clinical trials. Journal of Allergy and Clinical Immunology. 2017 May 1;139(5):1678-80.